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ABSTRACT Endothelin-1 (ET-1) mediates physiological responses via endothelin A (ETA) and B (ETB) receptors, which may
form homo- and heterodimers with unknown function. Here, we investigated ET-receptor dimerization using ﬂuorescence
resonance energy transfer (FRET) between receptors tagged with CFP (donor) and receptors tagged with tetracysteine-FlAsH
(fluorescein arsenical hairpin) (acceptor) expressed in HEK293 cells. FRET efﬁciencies were 15%, 22%, and 27% for ETA/ETA,
ETB/ETB, and ETA/ETB, respectively, and dimerization was further supported by coimmunoprecipitation. For all dimer pairs, the
natural but nonselective ligand ET-1 rapidly (#30 s) reduced FRET by .50%, but did not detectably reduce coimmunopre-
cipitation. ET-1 stimulated a transient increase in intracellular Ca21 ([Ca21]i) lasting 1–2 min for both homodimer pairs, and
these ET-1 actions on FRET and [Ca21]i elevation were blocked by the appropriate subtype-selective antagonist. In contrast,
ETA/ETB heterodimers mediated a sustained [Ca
21]i increase lasting .10 min, and required a combination of ETA and ETB
antagonists to block the observed FRET and [Ca21]i responses. The sensitive CFP/FlAsH FRET assay used here provides new
insights into endothelin-receptor dimer function, and represents a unique approach to characterize G-protein-coupled receptor
oligomers, including their pharmacology.
INTRODUCTION
Endothelins (ETs) are composed of a family of 21 amino acid
peptides (ET-1, ET-2, and ET-3) that regulate many physi-
ological systems (1). ET-1 is the predominant endothelin in
the cardiovascular system, where it binds to two distinct class
A G-protein-coupled receptor (GPCR) subtypes, endothelins
A (ETA) and B (ETB) (2,3). Despite 59% amino acid se-
quence identity, the ETA and ETB receptors function and
internalize with distinct patterns. Whereas ETA stimulation
leads to increased cardiac inotropy and vasoconstriction, ETB
stimulation results in vasodilation and possibly ET-1 clear-
ance (4–7). Although both receptors are internalized in a
similar fashion that depends upon G-protein-coupled recep-
tor kinase, arrestin, clathrin-coated pits, and dynamin, they
appear to be targeted to different intracellular fates. Once
internalized, the ETA receptor recycles back to the plasma
membrane, whereas the ETB receptor is targeted to lyso-
somes for degradation (8–10). The targeting of ETB receptors
for lysosomal degradation could explain the ET-1 clearance
role proposed for this receptor.
Emerging evidence suggests that GPCRs are capable of
forming both homo- and heterodimers that influence receptor
trafficking and function (11–13). Maturation of GABAB
receptors requires receptor dimerization at the Golgi to be
N-glycosylated for membrane trafficking (14). Altered re-
ceptor pharmacology and function were seen in b1 and b2
adrenergic receptors in intact adult mouse cardiomyocytes,
where heterodimerization reduced spontaneous receptor ac-
tivity and enhanced responsiveness to catecholamines (15).
In addition, evidence for GPCR dimers has been obtained in
vivo. In a study examining angiotensin and b-adrenergic
receptor heterodimers in mice, an AT-1 receptor blocker
decreased catecholamine-induced elevations in heart rate by
uncoupling b-adrenergic receptors from Gs (16). Finally,
models based on the crystal structure of bovine rhodopsin
suggest that dimers may be required to provide an optimal
footprint for G-protein insertion (17).
Despite coexpression of ET-receptor subtypes in a variety
of cells, little is known about their dimerization capabilities.
In astrocytes, where both ETA and ETB receptors may control
ET-1 clearance, addition of both ETA and ETB selective
antagonists (but not their individual application) was re-
quired to block ET-1 uptake (18). It has also been suggested
that ET-1 can function as a bivalent ligand that binds to the
ETA receptor via its N-terminus and to the ETB receptor via
its C-terminus, thereby inducing ET heterodimer formation
through a ligand bridge (19). The most direct evidence for
ETA and ETB homo- and heterodimers has emerged from
studies that combined extensive analysis of coimmunopre-
cipitation of tagged receptors with measurements of fluo-
rescence resonance energy transfer (FRET) using the cyan/
yellow fluorescent protein (CFP/YFP) FRET pair (20,21).
These initial investigations indicated considerable complex-
ity of ET-receptor interactions and suggested the need for
further experimentation to elucidate the dynamics and func-
tional consequences of their interactions.
In this study, using a different FRET pair, we examined the
ability of ETA and ETB receptors to form dimers and endeav-
ored to put the results into a physiological context by mea-
suring receptor function in parallel. CFP-tagged ET receptors
were used as the FRET donor, whereas the commercially
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available reagent FlAsH (fluorescein arsenical hairpin) was
used in place of the traditional acceptor YFP to exploit two
experimental advantages. The green spectral shift of FlAsH
provided greater spectral overlap with CFP, allowing for en-
hanced energy transfer between donor and acceptor (22). Use
of the FlAsH binding motif of 17 amino acids eliminated the
need for a second large 238-amino-acid fluorescent protein
probe (i.e., YFP) that could influence receptor function or
orientation in the membrane (22–26). Since FRET interac-
tions between a donor and acceptor are rapid and limited to
distances of,10 nm, we sought evidence for ‘‘short-range’’
protein-protein interactions that were dynamic and function-
ally relevant. Functional consequences of ET receptor di-
merization were investigated by monitoring intracellular
calcium changes using Ca21-sensitive fluorescent dyes. We
conclude from this study that the CFP/FlAsH FRET pair has
significant advantages over CFP/YFP for monitoring con-
formational changes in ET receptor dimers. Moreover, the
results provide evidence that ET receptor heterodimers have
pharmacological and Ca21 signaling properties distinct from
other forms of these receptors.
MATERIALS AND METHODS
Materials
Reagents were obtained from Sigma Chemical Company (St. Louis, MO),
unless otherwise stated. TransIT-LT1 was from Mirus (Madison, WI);
HEK293 cells from Stratagene (La Jolla, CA); X-rhod-1-AM, Fluo-4-AM,
TC-FlAsH II, Hank’s balanced salt solution (HBSS), Opti-MEM, horse se-
rum, and G418 from Invitrogen (Carlsbad, CA); cell culture plates from BD
Biosciences (Franklin Lakes, NJ); monoclonal CFP antibody (JL-8) and
pECFP-N1 plasmid vector from Clontech (Mountain View, CA); mono-
clonal c-myc (9E10) from Covance (Berkeley, CA); and protein G-sepharose
4 fast flow from GE Healthcare (Piscataway, NJ).
Generation of receptor constructs
Full-length human ETA (1–427) and ETB (1–442) receptor cDNA was ob-
tained from the University of Missouri-Rolla (http://www.cdna.org). ETA
cDNA (GenBank accession number AY275462) was inserted in frame into
the pECFP-N1 plasmid vector at NheI-AgeI sites to create a fused protein
construct (ETA-CFP). The c-myc epitope tag was inserted in frame onto the
N-terminus of ETA at NheI-HindIII sites, and a 17-amino-acid tetracysteine
binding sequence (AEAAAREACCPGCCARA) was inserted onto the
C-terminus of ETA at SalI-NotI sites in frame (myc-ETA-C4). ETB cDNA
(GenBank AY275463) was inserted in frame into the pECFP-N1 vector at
NheI-AgeI sites to create a fused protein construct (ETB-CFP). The c-myc
epitope tag was inserted in frame onto the N-terminus of ETB at NheI-HindIII
sites and the tetracysteine binding sequence onto the C-terminus of ETB at
SalI-NotI sites in frame (myc-ETB-C4).
Cell culture
HEK293 cells were maintained in minimal essential medium (MEM-a)
supplemented with 10% horse serum and antibiotics (50 units/mL penicillin,
50 mg/mL streptomycin, Gibco, Carlsbad, CA). Cells were grown at 37C
with 95% air, 5% CO2, and 25% humidity.
HEK293 cell transfection
Stable cell lines of myc-ETA-C4 and myc-ETB-C4 were created using LT-1
transfection reagent according to manufacturer instructions. Selection and
maintenance was obtained using MEM-a supplemented with 10% horse
serum and G418. Transient transfection of ETA-CFP and ETB-CFP con-
structs into stable cell lines was performed using LT-1.
Immunoprecipitation/immunoblotting
HEK293 cells stably expressing myc-ETA-C4 or myc-ETB-C4 on 10-cm
plates were transiently transfected with ETA-CFP or ETB-CFP and incubated
in growth media for 48 h. Cells were washed with phosphate-buffered saline
and permeabilized in lysis buffer (in mM, 150 NaCl, 25 Tris-HCl, 1 EDTA,
1 EGTA, 1 sodium orthovanadate, 1 sodium fluoride, and protease inhibitor
cocktail tablet, pH 7.4) with 1% Triton X-100 for 5 min on ice. In case of drug
treatment, cells were incubated with ET-1 or sarafotoxin s6c for 10 min at
room temperature before washing and cell lysis. Cells were scraped off with a
cell lifter, incubated in lysis buffer for 30 min on ice, and then spun at 13,0003
g for 10 min at 4C. The supernatant was incubated in 5 mg of monoclonal
anti-c-myc antibody overnight at 4C with gentle rocking, followed by a 3-h
incubation in protein G sepharose beads. Beads were then thoroughly
washed in lysis buffer and eluted with sodium dodecyl sulfate (SDS) sample
buffer. Samples were run on 12% SDS-polyacrylamide gels and transferred
to polyvinylidene fluoride membranes. Immunoblot analyses were con-
ducted with monoclonal anti-CFP primary antibody and horseradish per-
oxidase-conjugated secondary antibody from Santa Cruz Biotechnologies
(Santa Cruz, CA).
Ca21 indicator measurements
HEK293 cells stably expressing myc-ETA-C4 or myc-ETB-C4 on glass-
bottom culture dishes from MatTek (Ashland, MA) were transiently trans-
fected with ETA-CFP or ETB-CFP and incubated for 24 h. Cells were then
loaded with 4 mM Fluo-4 or X-rhod-1 in Opti-MEM (Gibco) for 1 h at 37C.
Cells were gently washed and maintained in room-temperature Ringer’s
solution with or without Ca21 (in mM, 125 NaCl, 5 KCl, 10 HEPES, 5
MgCl2, and 2 Ca
21). Imaging was performed with a Bio-Rad Radiance 2100
MP Rainbow laser scanning confocal microscope equipped with argon gas,
mixed gas (helium/neon) and red diode lasers. Changes in Ca21 indicator
fluorescence were measured in linescan mode using LaserSharp 6.0 software.
Fluo-4 and X-rhod-1 are nonratiometric calcium dyes and were therefore
used without calibration (i.e., fluorescence was not converted to free
[Ca21]i).
FRET
HEK293 cells stably expressing myc-ETA-C4 or myc-ETB-C4 were grown
onto 35-mm culture plates and transiently transfected with ETA-CFP or
ETB-CFP. Cells were then incubated for 24 h before FlAsH loading. Mea-
surements were made from several individual cells in each culture plate.
Normalized fluorescence values for a minimum of four cells from four plates
were averaged to obtain data as in Fig. 1 B.
FlAsH loading
Culture plates were thoroughly rinsed with commercial HBSS (in g/L, 0.14
CaCl2, 0.4 KCl, 0.06 KH2PO4, 0.1 MgCl2, 0.1 MgSO4, 8.0 NaCl, 0.35
NaHCO3, 0.048 Na2HPO4, and 1.0 D-glucose) and covered with 500 mL of
freshly made loading solution consisting of 10 mM EDT and 1 mM FlAsH-
EDT2 in HBSS. Dishes were incubated at room temperature for 2 h in the
dark with gentle shaking. The FlAsH-EDT2 loading solution was then
thoroughly rinsed with HBSS before imaging.
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FlAsH unloading
A freshly made stock solution of 15 mM 2,3-dimercapto-1-propanol (BAL)
in HBSS was used. The stock solution was diluted threefold in the solution
bathing the imaged cells to yield a final BAL concentration of 5 mM. Plates
were incubated in the BAL solution for 10 min, followed by image capture.
Microscope
Global epifluorescence was captured with a cooled CCD DP-70 camera
(Olympus, Melville, NY) using a 203/0.95-NA water-immersion objective
in an upright Olympus BX51 microscope. Excitation was provided by a
100-W Hg lamp filtered with standard bandpass excitation/emission filter
cubes. Chroma 31036 (excitation 436/20 nm, emission 480/30 nm, dichroic
455) was used for CFP, and Chroma 41028 (excitation 500/20 nm, emission
535/30 nm, dichroic 515) was used for FlAsH.
Image analysis
Images of 680 3 512 pixels were acquired at 8-bit resolution without com-
pression of the A/D conversion scale. Integration time (250 ms) and camera
sensitivity settings were set constant. Five images were averaged to improve
the signal/noise ratio and composite images were analyzed with NIH image
software. Mean pixel intensities were measured in regions of interest of 100–
200 pixels (0.04 mm/pixel). Background intensities were measured near the
regions of interest and were subtracted. Mean pixel intensities for CFP and
FlAsH emissions were in the range 30–150 on a scale of 0–255.
FRET ratio/efﬁciency
FRET is characterized by the increase in acceptor (FlAsH) emission con-
comitant with a decrease in donor (CFP) emission. This ratio is calculated as
follows: (CFP emission after FlAsH loading and after BAL wash)/(CFP
emission after FlAsH loading and before BAL wash). From this ratio, the
FRET efficiency was determined according to 1  [1/FRET ratio].
[125I]-ET-1 binding experiments
HEK293 cells stably expressing myc-ETA-C4 or myc-ETB-C4 on 35-mm
plates were transiently transfected with ETA-CFP or ETB-CFP, or mock-
transfected, and sustained in growth medium for 24 h. Cells were incubated
in 100 pmol [125I]-ET-1 with (nonspecific binding) or without (total binding)
pretreatment with 10 nM cold ET-1. Cells were then thoroughly washed with
ice-cold phosphate-buffered saline and solubilized with lysis buffer. Samples
were spun at 50003 g for 5 min and supernatant was added to 10 mL vials
with Bio-Safe II scintillation cocktail (Mount Prospect, IL). Radioactivity
was measured in a gamma-counter (PerkinElmer, Boston, MA). Specific
binding was taken as the difference between total and nonspecific binding
and normalized to milligrams of protein.
Statistics
Paired samples with and without agonist or antagonist were compared with
an unpaired two-tailed Student’s t-test using the commercial software Excel.
For statistical analysis of more than two experimental conditions, a one-way
ANOVA with Tukey’s post-test was applied using a public domain website
(http://faculty.vassar.edu/lowry/VassarStats.html). In all cases, values of p,
0.05 were taken to represent statistically significant differences.
RESULTS
Expression of endothelin receptor constructs in
HEK293 cells
Full-length human endothelin A (ETA) or B (ETB) receptors
were C-terminally tagged with CFP (ETA-CFP and ETB-CFP)
or N-terminally tagged with the c-myc epitope and C-terminally
tagged with a tetracysteine (C4) motif (myc-ETA-C4 and myc-
ETB-C4) to create fused receptor constructs. Transient trans-
fection of CFP constructs revealed that typically 30–50% of
HEK293 cells expressed the receptor constructs. The myc-ETA-
C4 and myc-ETB-C4 constructs were each expressed in a sep-
arate stable HEK293 cell line to ensure reproducible expression
levels in the entire cell population from experiment to experi-
ment. To assure that the CFP and myc/C4-tagged endothelin
receptor constructs were properly trafficked to the plasma
membrane, transfected HEK293 cells were visualized in optical
detection channels for CFP and FlAsH. As shown in Fig. 1 A,
both CFP- and myc/C4-FlAsH-tagged ETA and ETB constructs
were distinctly targeted to the plasma membrane of HEK293
cells.
Time course and reversibility of
FlAsH incorporation
Stably transfected myc-ETA-C4 or myc-ETB-C4 in HEK293
cells were transfected with ETA-CFP or ETB-CFP, and fluo-
rescence emission was measured every 4 min (details in
Fig. 1 legend) in the CFP and FlAsH channels over a 100-min
time course. Addition of 1mM FlAsH resulted in a systematic
drop in CFP fluorescence concomitant with a rise in FlAsH
fluorescence, with both signals becoming saturated after;70
min (Fig. 1 B). Incubation with 5 mM BAL, which displaces
FlAsH from the tetracysteine binding site, quickly washed
away the FlAsH acceptor and restored CFP fluorescence to
near basal conditions. This step demonstrated a ready re-
versibility of the FRET signal. The recovery of CFP fluo-
rescence after BAL addition to near basal levels showed that
the effects of photobleaching on the system were minimal.
Calculation of the FRET efficiency from this data was as
follows: FRET efficiency ¼ 1  [1/FRET ratio], where
FRET ratio ¼ (CFP emission after FlAsH loading and BAL
wash)/(CFP emission after FlAsH loading and before BAL
wash).
ET receptor homo- and heterodimers in HEK293
cells by FRET
HEK293 cells stably expressing myc-ETA-C4 or myc-ETB-
C4 were transiently transfected with ETA-CFP or ETB-CFP.
In all cases, the transiently transfected construct was the
FRET donor (CFP) and was expressed at a lower average
level than the stably expressed construct (C4), which was the
FRET acceptor (Table 1). Thus, with a saturating (or near-
saturating) amount of FRET acceptor relative to donor, the
system was optimized for reproducible FRET measurements.
After equilibration with FlAsH, as shown in Fig. 1 B, FRET
efficiencies of 15 6 3%, 22 6 2% and 27 6 4% were ob-
served for ETA/ETA, ETB/ETB, and ETA/ETB combinations,
respectively. These values were reproducible among differ-
ent regions of the plasma membrane and from cell to cell,
plate to plate, and experiment to experiment. FRET effi-
Endothelin Receptor Dimers 485
Biophysical Journal 95(1) 483–492
ciencies between 15% and 27% are indicative of robust en-
dothelin-receptor homo- and heterodimerization. Incubation
with FlAsH in the absence of myc-ETA-C4 or myc-ETB-C4,
but in the presence of CFP-tagged ETA or ETB receptors did
not produce a FRET signal. Transfection of nontagged ETA
or ETB receptors, or CFP alone, to stably expressing myc-
ETA-C4 or myc-ETB-C4 cells, or exposure of the stable cell
lines to FlAsH alone, also gave no FRET signal (Fig. 1 B).
The data indicate that the FRET signal is limited to CFP-
tagged and FlAsH-bound C4-tagged receptors and therefore
provides evidence for short-range protein-protein interac-
tions between receptors.
Evidence for specificity of the FRET signal was obtained
by a pharmacological analysis. Addition of ET-1 (10 nM)
significantly reduced FRET efficiency in all dimers (Fig. 2).
As a control, addition of 10 nM ET-1 to cells expressing
CFP-tagged ETA or CFP-tagged ETB alone, or FlAsH-bound
myc-ETA-C4 or FlAsH-bound myc-ETB-C4 alone, had no
effect on CFP or FlAsH fluorescence. Thus, under conditions
where no FRET was observed, ET-1 did not influence probe
fluorescence. The effects of ET-1 on FRET efficiency were
blocked by preincubation of ETA homodimers with the ETA
selective antagonist BQ123 or ETB homodimers with the
ETB selective antagonist BQ788 (Fig. 2). It is interesting that
the FRET change observed for ETA/ETB heterodimers in
response to ET-1 required the presence of both BQ123 and
BQ788 for effective blockade (Fig. 2). Receptor subtype
specificity was further demonstrated by incubation with
30 nM sarafotoxin s6c, an ETB selective agonist. Sarafotoxin
s6c reduced FRET efficiency by a similar magnitude to ET-1,
but only in dimers containing ETB (Fig. 2).
The FRET change observed with 10 nM ET-1 occurred
within 30 s (the shortest time tested), as indicated by the
dramatic and abrupt increase in CFP fluorescence after ad-
dition of ET-1 (Fig. 3). This rapid onset of the ET-1 response
suggested that ET-1 reduces FRET efficiency predominantly
by ligand binding and subsequent conformational change(s)
rather than by processes occurring in the minute time do-
main, such as receptor internalization. Moreover, in the
presence of 450 mM sucrose, which has previously been
shown to prevent clathrin-mediated internalization (27),
ET-1 caused changes in FRET efficiency similar in magni-
tude and direction to those observed in the absence of su-
crose (15% to 7% for ETA/ETA, 22% to 15% for ETB/ETB,
and 27% to 10% for ETA/ETB). In all dimers, addition of
antagonists alone also tended to reduce FRET efficiency (as
in Fig. 2), possibly representing an antagonist-induced dimer
rearrangement. This is in agreement with a study showing
that BQ123 can bind and induce a conformational change in
ETA (28); in our system, this phenomenon requires further
investigation.
Receptor dimers by coimmunoprecipitation
In HEK293 cells stably expressing myc-tagged ETA or ETB
receptors, immunoblots with an anti-c-myc monoclonal an-
tibody detected a band at;50 kD, corresponding to the myc-
FIGURE 1 Localization and FRET interactions of donor (CFP)- and acceptor (FlAsH)-tagged ET receptors. Tetracysteine (C4)-fused constructs were made
stable in HEK293 cells in all experiments. (A) ETA-C4 transfected with ETA-CFP (a and b) or ETB-CFP (e and f) and ETB-C4 transfected with ETB-CFP (c and
d) were visualized in the CFP channel (left) or the FlAsH channel (right). (B) Fluorescence intensity was measured once every 4 min (with 53 0.25 s¼ 1.25 s
total exposure to excitation light per measurement) in both CFP and FlAsH channels in ETA-C4 (a, b, g, and h) or ETB-C4 (d and e) transfected with ETA-CFP
(a and b), or ETB-CFP (d, e, g,and h); 1mM FlAsH added at the arrow; 5 mM BAL added at the arrowhead. Summary of FRET measurements of ETA-C4 (c and
i) or ETB-C4 (f) transfected with ETA-CFP (c) or ETB-CFP (f and i); A-CFP, ETA-CFP; A, ETA; A-C4, ETA-C4; B-CFP, ETB-CFP; B, ETB; B-C4, ETB-C4;
*p , 0.05 by one-way ANOVA with Tukey’s post-test indicates significant difference from all others.
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ETA-C4 or myc-ETB-C4 receptor, that was absent in HEK293
cells alone. In addition, CFP-tagged ETA or ETB receptors
expressed in HEK293 cells gave a band at ;75 kD on im-
munoblots with an anti-CFP monoclonal antibody. Therefore,
the c-myc and CFP antibodies were deemed suitable for
coimmunoprecipitation analysis. Next, stably expressed myc-
ETA-C4 or myc-ETB-C4 receptors were transfected with
ETA-CFP or ETB-CFP and subjected to detergent solubili-
zation. ETA and ETB receptors were immunoprecipitated with
the c-myc antibody and immunoblotted with the CFP anti-
body. A band at ;75 kD corresponding to the CFP-tagged
ETA or ETB receptor was found in myc-ETA-C4/ETA-CFP
and myc-ETB-C4/ETB-CFP, indicative of ETA and ETB ho-
modimers (Fig. 4). In addition, a band at ;75 kD corre-
sponding to ETB-CFP was found in myc-ETA-C4/ETB-CFP,
indicative of heterodimers. No band was seen in mock-
transfected myc-ETA-C4 and myc-ETB-C4 stable cell lines.
To rule out the possibility of receptor aggregation after sol-
ubilization, the following cell extracts were mixed after
receptor solubilization but before immunoprecipitation: myc-
ETA-C4 plus ETA-CFP (nonspecific ETA homodimers), myc-
ETB-C4 plus ETB-CFP (nonspecific ETB homodimers), and
myc-ETA-C4 plus ETB-CFP (nonspecific ETA heterodimers).
In agreement with a previous study (20), mixtures of cell
extracts failed to result in coimmunoprecipitation of recep-
tors.
It is important that preincubation of cells expressing ET
receptors with the nonselective agonist ET-1 or the ETB se-
lective agonist sarafotoxin s6c had no effect on the ability to
coimmunoprecipitate the tagged receptors (Fig. 4). These
observations indicate that agonists do not promote dimer
formation, nor do they dissociate dimers. Coimmunoprecip-
FIGURE 2 Ligand effects on FRET
for homo- and heterodimers. HEK293
cells stably expressing ETA-C4 (A and
C) or ETB-C4 (B) were transfected with
ETA-CFP (A) or ETB-CFP (B and C).
Cells were preincubated with 10 nM
ET-1 or 30 nM s6c for 10 min at room
temperature followed by FRET analysis.
Cells treated with antagonists (1 mM
BQ123 and BQ788) were preincubated
for 10 min before ligand addition.
Values are mean 6 SE from at least 20
cells. *p , 0.05 by Student’s t-test.
TABLE 1 Radioligand binding characteristics of endothelin receptor dimers
Receptors Bmax (pmol/mg) Percent of control* C4/CFP
y Adjusted C4/CFP Adjusted ETA/ETB
Homodimers
myc-ETA-C4 (control) 0.96 6 0.06 100
myc-ETA-C4/ETA-CFP 1.53 6 0.05
z 159 1.69:1 0.85:1
myc-ETA-C4/ETA-CFP,
1BQ123
0.18 6 0.08z 12
myc-ETB-C4 (control) 7.07 6 0.06 100
myc-ETB-C4/ETB-CFP 12.06 6 1.24
z 171 1.41:1 0.71:1
myc-ETB-C4/ETB-CFP,
1BQ788
0.24 6 0.08z 2
Heterodimers
myc-ETA-C4/ETB-CFP 1.40 6 0.06
z 146 2.17:1 1.09:1 1.09:1
myc-ETA-C4/ETB-CFP,
1BQ123/BQ788
0.05 6 0.02§ 4
myc-ETB-C4/ETA-CFP 9.91 6 0.77
z 140 2.50:1 1.25:1 0.80:1
myc-ETB-C4/ETA-CFP,
1BQ123/BQ788
0.24 6 0.10§ 2
Binding of [125I]-ET-1 was performed as described in Materials and Methods. Bmax is the density of specific ET-1 binding sites in pmol/mg protein measured
in HEK293 cells. Data are the mean 6 SE of at least three independent experiments, each performed in duplicate. BQ123 and BQ788, each applied at 1 mM,
were used as receptor antagonists for ETA and ETB, respectively.
*HEK293 cells stably expressing myc-ETA-C4 or myc-ETB-C4 served as controls (100% specific binding). After transient transfection with ETA-CFP or
ETB-CFP, the parameter ‘‘percent of control’’ represents a measure of specific ET-1 binding to stably plus transiently transfected receptors.
yThe molar ratio of C4 to CFP tagged receptors calculated from ET-1 binding before (C4) and after (CFP) transient transfection. Adjusted C4/CFP ratio is
calculated by assuming a uniform receptor density in stable cell lines and a 50% transient transfection efficiency. Adjusted ETA:ETB is the molar ratio of
receptor subtypes estimated from the adjusted C4/CFP ratio.
zp , 0.05 by Student’s t-test between dimer and myc-ETA-C4 or myc-ETB-C4 control.
§p , 0.05 by Student’s t-test between dimer and myc-ETA-C4:ETB-CFP or myc-ETB-C4:ETA-CFP.
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itation and FRET measurements revealed different but
complementary aspects of ET dimerization.
Receptor density and pharmacology by
[125I]-ET-1 binding
A potential limitation of receptor overexpression in heterol-
ogous cell systems is the possibility that receptors achieve
supraphysiological densities on the cell surface. Therefore,
ETA and ETB receptor densities were measured using [
125I]-
ET-1 binding in HEK293 cells (Table 1). The two stable
HEK293 cell lines expressed 0.96 6 0.06 pmol/mg protein
for myc-ETA-C4 cells and 7.07 6 0.72 pmol/mg protein for
myc-ETB-C4. Upon subsequent transient transfection of
ETA-CFP or ETB-CFP to generate homodimers, specific
[125I]-ET-1 binding increased by;60% to 1.536 0.05 pmol/
mg and 12.06 6 1.24 pmol/mg, respectively (Table 1).
Specific binding was blocked by the appropriate antagonist,
BQ123 for ETA homodimers and BQ788 for ETB homo-
dimers (Table 1). For as yet unknown reasons, the ETB
constructs appeared to express more robustly than ETA
constructs for both transient transfection and stable expres-
sion. Nevertheless, these data are consistent with other esti-
mates of ET receptor density in heterologous expression
systems (9,10,20).
HEK293 cells expressing ETA/ETB heterodimers were
also evaluated by [125I]-ET-1 binding. Transient transfection
of ETB-CFP in the myc-ETA-C4 cell line increased [
125I]-
ET-1 binding by ;50% (Table 1). The reciprocal order of
expression involving transient transfection of ETA-CFP in
the myc-ETB-C4 cell line also increased specific binding by
;40%, despite different total levels of receptor expression.
This provided a useful comparison between HEK293 cells
expressing significantly different overall densities of ET-1
binding sites, 1.40 6 0.06 pmol/mg vs. 9.91 6 0.77 pmol/
mg, and somewhat different ETA/ETB ratios (1.09:1 vs.
0.80:1, Table 1). In both cases, complete blockade of [125I]-
ET-1 binding required the presence of both BQ123 and
BQ788 (Table 1). In contrast, individual application of sub-
type-selective antagonists resulted in only partial blockade of
[125I]-ET-1 binding to heterodimers. For example, BQ123
reduced specific [125I]-ET-1 binding from 1.40 6 0.06 to
0.49 6 0.09 (66% blockade) whereas BQ788 reduced spe-
cific [125I]-ET-1 binding from 1.40 6 0.06 to 0.92 6 0.05
(34% blockade), consistent with the proportions of ETA and
ETB expressed.
Functional consequences of
receptor dimerization
To test the functional consequences of receptor homo- and
heterodimerization, HEK293 cells expressing ET receptor
FIGURE 4 Coimmunoprecipitation of receptor constructs expressed in
HEK293 cells. Stably transfected myc-ETA-C4 (left and right) or myc-ETB-
C4 (middle) were transfected with ETA-CFP (left) or ETB-CFP (middle and
right). Cells were subjected to no treatment, 10 nM ET-1, or 30 nM s6c for
10 min, solubilized in detergent, then immunoprecipitated with a monoclo-
nal anti-myc antibody. Immunoprecipitated proteins were then immuno-
blotted using a monoclonal anti-CFP antibody.
FIGURE 3 Time course of ET-1 effects on FRET. Stably expressed C4-
tagged ETA-C4 (A and C) or ETB-C4 (B) were transfected with ETA-CFP (A)
or ETB-CFP (B and C) in HEK293 cells. Cells were exposed to 10 nM ET-1
(arrow) and CFP fluorescence was measured at 30 s, 60 s, and 4 min. Values
are mean 6 SE from at least eight cells. Not shown here was a concomitant
(but much smaller) decline in FlAsH fluorescence.
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constructs were loaded with Ca21-sensitive dyes Fluo-4 or
X-rhod-1. Cells were stimulated with agonists in the presence
and absence of extracellular Ca21. A representative experi-
ment is shown in Fig. 5 A. ET-1 stimulation of HEK293 cells
expressing myc-ETA-C4/ETA-CFP and myc-ETB-C4/ETB-
CFP resulted in a transient increase in Ca21 indicator fluo-
rescence within 1–2 min that returned toward basal levels
after 2–4 min (Fig. 5 B). This transient response was similar
to what was observed when the C4- or CFP-tagged receptors
were expressed individually (29). Preincubation with the
appropriate subtype-selective antagonist blocked this effect
of ET-1 on intracellular Ca21. Removal of extracellular Ca21
in the bathing solution had no effect on the response of ETA
homodimers, but ablated the response of ETB homodimers to
ET-1 (Fig. 5 B). This is consistent with ETA receptors mo-
bilizing Ca21 through an IP3-regulated intracellular store,
whereas ETB receptors rely more on Ca
21 influx from the
extracellular solution (1–3,30). The ETB selective agonist
sarafotoxin s6c resulted in a similar transient increase in in-
tracellular calcium, but only with ETB homodimers. To ad-
dress whether the transient nature of the homodimer response
was due to dye bleaching or leakage, HEK293 cells were
stimulated with the Ca21 ionophore A23187. This resulted in
a sustained increase of indicator fluorescence that lasted
.30 min (data not shown), arguing against time-dependent
changes in dye performance.
ET-1 stimulation of heterodimers did not show the tran-
sient Ca21 increase seen with homodimers, but instead re-
sulted in a Ca21 signal that was sustained throughout the
10-min test period. Ca21 elevation mediated by heterodimers
was also not influenced by removal of extracellular Ca21,
consistent with involvement of intracellular Ca21 stores. The
sustained Ca21 elevation mediated by heterodimers could not
be blocked by standard doses of the antagonists BQ123 or
BQ788 alone, but was completely inhibited by application of
BQ123 and BQ788 in combination at the same doses (Fig.
FIGURE 5 Intracellular Ca21 mobili-
zation mediated by receptor homo- and
heterodimers. (A) Visualization of Fluo-
4 loaded HEK293 cells stably ex-
pressing ETA-C4 and transfected with
ETA-CFP stimulated by ET-1. (B) Sta-
ble ETA-C4 transfected with ETA-CFP
(upper) or ETB-CFP (lower), and stable
ETB-C4 transfected with ETB-CFP (mid-
dle) were subjected to ligand treatment;
extracellular solution with (squares) or
without Ca21 (triangles). Bar graphs sum-
marize changes in indicator fluorescence
after 1 min averaged over five to eight
cells. Ca21 signals mediated by hetero-
dimers were sustained for.10 min even
in the presence of BQ123 or BQ788
alone. *p , 0.05 by one-way ANOVA
with Tukey’s post-test indicates signif-
icant difference from all others, except
those marked with two asterisks (**),
and ** indicates significant difference
among all others except those marked
with one asterisk (*).
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5 B). Heterodimers composed of myc-ETA-C4/ETB-CFP or
myc-ETB-C4/ETA-CFP behaved indistinguishably. It is in-
teresting that despite the fact that the ETB selective antago-
nist sarafotoxin s6c could bind to ETA/ETB heterodimers,
sarafotoxin s6c was unable to trigger Ca21 mobilization for
reasons that are not entirely clear.
Nevertheless, the data provide unique ligand binding and
functional profiles for each of the ET receptor dimer species.
ETA/ETA homodimers mediated a transient intracellular-
store-dependent Ca21 increase with traditional ETA receptor
pharmacology. ETB/ETB homodimers mediated a transient
extracellular-pool-dependent Ca21 increase with traditional
ETB receptor pharmacology. Finally, ETA/ETB heterodimers
mediated a sustained intracellular-store-dependent Ca21 in-
crease with unique pharmacological properties. Specifically,
heterodimers required combined ETA and ETB antagonism to
inhibit ET-1 binding, subsequent conformational changes,
and functional coupling.
DISCUSSION
The purpose of this study was to investigate homo- and
heterodimerization of ETA and ETB receptors in HEK293
cells with an emphasis on elucidating the functional con-
sequences of dimerization. The FRET efficiencies for ET
receptor homo- and heterodimers reported here were in
qualitative agreement with previous studies that examined
ET receptor dimerization using CFP- and YFP-tagged re-
ceptors (20,21). Use of the FlAsH acceptor in place of YFP
allowed for robust signals including FRET efficiencies up to
27% for ETA/ETB heterodimers with the microscope ar-
rangement used. In previous studies with the CFP/YFP pair,
receptor binding by ET-1 had no statistically significant ef-
fects on FRET efficiency, whereas in this study, use of the
CFP/FlAsH pair revealed unambiguous ligand-dependent
changes in FRET efficiency. Thus, to our knowledge, this
is the first report of a FRET assay for monitoring ligand-
induced conformational changes in ET-receptor dimers.
FlAsH based FRET has been successfully employed to
monitor conformational changes in adenosine receptor mono-
mers (23), and a bioluminescence resonance energy transfer
assay has been shown to detect isoproterenol binding to b2-
adrenergic receptor homodimers (31).
We proceeded to exploit this FRET signal to reveal the
pharmacology of ET receptor dimers, and compared these
properties with receptor pharmacology monitored by Ca21
mobilization. The data provide strong evidence for functional
and pharmacological properties that are unique to ET-receptor
heterodimers. Specifically, we provided evidence that heter-
odimers undergo a conformational change that precedes a
sustained (rather than transient) intracellular Ca21 elevation
in response to ET-1. This sustained intracellular Ca21 ele-
vation induced by ET-1 is in agreement with the results of a
previous study (32). Moreover, ET-1 responses mediated
byheterodimers required both an ETA and an ETB subtype-
selective antagonist for effective inhibition of the conforma-
tional change, as well as the sustained Ca21 response. Thus, if
we can extrapolate these results to ET receptors in native
tissues, subtype-selective antagonists may be relatively inef-
fective at blocking heterodimer function, compared to a
mixture of antagonists or to antagonists with mixed speci-
ficity. Further investigation is required to reveal the precise
properties of ET receptors in native tissues.
In contrast to heterodimers, ET-1 responses mediated by
homodimers displayed a transient intracellular Ca21 eleva-
tion, which was inhibited by inclusion of only the appropriate
receptor subtype-selective antagonist: BQ123 for ETA ho-
modimers and BQ788 for ETB homodimers. The FRET
changes induced by ET-1 binding were also inhibited by the
appropriate subtype-selective antagonist. Examination of the
ETB selective agonist sarafotoxin s6c showed the expected
pharmacology, causing a.50% decrease in FRET that again
preceded a transient elevation of intracellular Ca21. As ex-
pected, sarafotoxin s6c only affected ETB homodimers, not
ETA homodimers. Thus, the pharmacological profile of ho-
modimers monitored in this way was indistinguishable from
isolated ETA and ETB binding sites and/or functional mono-
mers. It has been previously demonstrated that fluorescent
probes fused onto the C-terminus of ETA and ETB receptors
or the c-myc epitope included on the N-terminus of the re-
ceptors have only minimal effects on function and ligand
binding of ET receptors (9,20). Insertion on the C-terminus of
other similar optical tags, including the C4 motif, have also
been shown to have no effect on function in a variety of re-
ceptors (22–26,31). Recently, we have provided evidence
that the fluorescent probes and the myc/C4 tags have minimal
effects on receptor expression, trafficking, and overall re-
ceptor function (29).
In this study, we also sought to determine whether ET
receptor dimerization was required for normal receptor traf-
ficking to the cell surface of HEK293 cells. ET receptor
FRET signals were not detected within intracellular com-
partments, but were only observed in the plasma membrane.
This interpretation was further supported by examining an
ETA receptor point mutation (F376A) within a highly con-
served rhodopsinlike GPCR export motif on the C-terminus
(33,34). This mutation prevented surface membrane expres-
sion and effectively eliminated FRET throughout the cells for
all dimers containing ETA (data not shown). Thus, assuming
that the F376A mutation had no effect on dimerization itself,
the data suggest that receptors accumulate at the cell surface
before dimerization proceeds. The results do not support a
role for dimerization in ET receptor trafficking to the cell
surface, at least in HEK293 cells. The extent of dimerization
appeared to be largely independent of ligand, as pre-
incubation with ET-1 or sarafotoxin s6c had no effect on the
ability to coimmunoprecipitate tagged receptors. Therefore,
overall, the data suggest that ET receptors form long-lived
‘‘constitutive’’ homo- and heterodimers that do not appear
before surface membrane expression and whose overall de-
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gree of association is not detectably influenced by ligand
binding. These observations differ from other GPCRs such as
the GABAB and b2-adrenergic receptors, which require di-
merization for membrane trafficking (14,35) and differ from
receptor tyrosine kinases, where ligands promote dimeriza-
tion by effectively cross-linking monomeric receptors (36).
Taken together, these considerations demonstrate the com-
plexity and diversity of cell surface signaling and trafficking
even within the GPCR superfamily.
What are the physiological implications of the unique
functional characteristics of ET receptor heterodimers? The
sustained Ca21 signaling exhibited by ET heterodimers, even
in the absence of extracellular Ca21, suggests novel signaling
mechanisms involving intracellular Ca21 stores. The sus-
tained, rather than transient or oscillatory, nature of the Ca21
increase raises the intriguing possibility that ET-1 is capable
of initiating unique patterns of temporally and spatially con-
trolled intracellular Ca21 signals. For example, in rabbit and
mouse ventricular myocytes, global systolic Ca21 transients
are known to initiate cyclic contractile activity, whereas ET-1
can initiate a completely distinct IP3-mediated Ca
21 response
(possibly sustained) that stimulates hypertrophic gene tran-
scription (37). The ability of ET heterodimerization to expand
receptor signaling diversity underscores the importance of
understanding the pharmacological and functional conse-
quences of these interactions.
The observation that each subtype-selective antagonist
binds independently to heterodimers, but when used alone
cannot block FRET changes or sustained Ca21 mobilization,
leads to several important insights. First, each ET-1 binding
site in the heterodimer appears capable of independently
activating conformational changes and coupling to sustained
Ca21 signaling. Second, the sustained Ca21 response is
likely mediated by heterodimers, and is not the result of a
unique combination of intracellular signaling events initiated
by activation of separate ETA and ETB receptors. If sustained
Ca21 responses were due to activation of separate cell surface
ETA and ETB, then antagonists would be expected to convert
the sustained Ca21 response to a transient one. Third, the
requirement for both ETA- and ETB-selective antagonists to
inhibit function may be a hallmark of ET receptor hetero-
dimer pharmacology. This is clearly not the whole story,
however, and further investigation is required to determine
the specific role(s) of each receptor ‘‘subunit’’ in heterodimer
signaling. For example, in this study, the ETB-selective ag-
onist sarafotoxin induced a conformational change in het-
erodimers, but failed to produce a functional Ca21 increase.
Sarafotoxin s6c appears capable of binding to ETB within the
heterodimer, but is not capable of initiating the proper
G-protein coupling necessary for signaling within the heter-
odimer. A more complete systematic analysis of agonist and
antagonist binding to heterodimers is of interest and is cur-
rently underway.
It is well established that plasma ET-1 levels are elevated
in patients with various chronic conditions including chronic
heart failure (CHF), atherosclerosis, diabetes, and certain
malignant tumors. For CHF, efforts to uncover the efficacy of
ET receptor antagonists have yielded mixed results. Infusion
or oral administration of the dual selective ETA/ETB antag-
onist Bosentan improved systemic and pulmonary hemody-
namics (38–41), and infusion of the dual selective ETA/ETB
antagonist Tezosentan reduced peripheral resistance and in-
creased cardiac power in CHF patients (42). Conversely,
results of the ENABLE (Endothelin Antagonist Bosentan for
Lowering Cardiac Events in Heart Failure) study using low
doses of orally administered Bosentan failed to demonstrate
efficacy in severe heart failure patients (43). Effective ther-
apeutic intervention for these diseases will almost certainly
depend upon developing a clearer understanding of the role
of ET receptor dimerization in these chronic conditions. An
intriguing possibility is that the efficacy of current ET re-
ceptor antagonists could be improved by establishing which
ones preferentially block monomers, homodimers, and/or
heterodimers. In this regard, the optical assays described here
should permit a systematic evaluation of which antagonists
and agonists target which dimeric ET receptor species and at
what doses.
This work was supported by grants RO1HL081386 and T32-HL07936
from the National Institutes of Health.
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